Article

Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury

Dept Comparative Biology &Safety Sciences, 1201 Amgen Court West, Seattle WA 98119.
Arthritis & Rheumatology (Impact Factor: 7.87). 03/2013; 65(3). DOI: 10.1002/art.37802
Source: PubMed

ABSTRACT OBJECTIVE.: Sclerostin plays a major role in regulating skeletal bone mass but its effects in articular cartilage are not known. The purpose of this study was to determine if genetic loss or pharmacological inhibition of sclerostin impacted knee joint articular cartilage. METHODS.: Sclerostin expression was determined in articular cartilage and bone tissue taken from mouse, rat and human specimens, including patients with osteoarthritis (OA). Sclerostin knockout (KO) mice and pharmacological inhibition of sclerostin with sclerostin monoclonal antibody (Scl-Ab) in aged male and ovariectomized (OVX) female rats were used to study effects on joint pathology. The rat medial meniscus tear (MMT) model of OA was used to investigate the pharmacological efficacy of systemic Scl-Ab or intra-articular delivery of sclerostin antibody Fab fragment (Scl-Fab). RESULTS.: Sclerostin expression was detected in rodent and human articular chondrocytes. No difference was observed in the magnitude or distribution of sclerostin expression in normal and OA cartilage or bone. Sclerostin KO mice showed no difference in knee joint pathology compared to age-matched wild-type (WT) mice. Pharmacological treatment of intact aged male rats or OVX female rats with Scl-Ab had no effect on morphology of articular cartilage. In the rat MMT model, pharmacological treatment of animals with either systemic Scl-Ab or intra-articular injection of Scl-Fab had no effect on lesion development or severity. CONCLUSION.: Genetic absence of sclerostin does not alter normal development of age-dependent OA in mice and pharmacological inhibition of sclerostin with Scl-Ab does not impact articular cartilage in rats with post-traumatic OA. © 2012 American College of Rheumatology.

Full-text

Available from: Qing-Tian Niu, Feb 16, 2015
0 Followers
 · 
83 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionSclerostin is a Wnt inhibitor produced by osteocytes that regulates bone formation. Because bone tissue contributes to the development of osteoarthritis (OA), we investigated the role of sclerostin in bone and cartilage in a joint-instability model in mice.Methods Ten-week-old SOST-knockout (SOST-KO) and wild-type (WT) mice underwent destabilization of the medial meniscus (DMM). We measured bone volume at the medial femoral condyle and osteophyte volume and determined the OA score and expression of matrix proteins. Primary murine chondrocytes were cultured with Wnt3a and sclerostin to assess the expression of matrix proteins, proteoglycan release and glycosaminoglycan accumulation.ResultsSclerostin was expressed in calcified cartilage of WT mice with OA. In SOST-KO mice, cartilage was preserved despite high bone volume. However, SOST-KO mice with DMM had a high OA score, with increased expression of aggrecanases and type-X collagen. Moreover, SOST-KO mice with OA showed disrupted anabolic/catabolic balance and cartilage damage. In primary chondrocytes, sclerostin addition abolished Wnt3a-increased expression of a disintegrin and metalloproteinase with thrombospondin motifs, matrix metalloproteinases, and type-X collagen by inhibiting the canonical Wnt pathway. Moreover, sclerostin inhibited Wnt-phosphorylated c-Jun N-terminal kinase (JNK) and rescued the expression of anabolic genes. Furthermore, sclerostin treatment inhibited both Wnt canonical and non-canonical JNK pathways in chondrocytes, thus preserving metabolism.Conclusion Sclerostin may play an important role in maintaining cartilage integrity in OA.
    Arthritis Research & Therapy 02/2015; 17(1):24. DOI:10.1186/s13075-015-0540-6 · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sclerostin is a small protein expressed by the SOST gene in osteocytes, bone cells that respond to mechanical stress applied to the skeleton and appear to play an important role in the regulation of bone remodeling. When sclerostin binds to its receptors on the cell surface of osteoblasts, a downstream cascade of intracellular signaling is initiated, with the ultimate effect of inhibiting osteoblastic bone formation. Recent studies have shown that the SOST gene is also expressed by articular chondrocytes and that modulation of its activity may have effects on articular cartilage and subchondral bone. The role of sclerostin in the pathogenesis of osteoarthritis in humans has not yet been defined, and the potential utility of treating osteoarthritis with interventions that alter sclerostin is not known. Rare genetic skeletal disorders in humans with low sclerostin levels, such as sclerosteosis and van Buchem disease, have been associated with a high bone mineral density (BMD) phenotype and low risk of fractures. This has led to the concept that antisclerostin interventions might be useful in the treatment of patients with osteoporosis and skeletal disorders associated with low bone mass. Compounds that inhibit sclerostin have been shown to stimulate bone formation and reduce bone resorption, with a robust increase in BMD. Investigational monoclonal antibodies to sclerostin, including romosozumab, blosozumab, and BPS804, have advanced to phase II clinical trials or beyond. If antisclerostin therapy is found to have beneficial effects on clinical endpoints, such as reduction of fracture risk or improvement in quality of life in patients with osteoarthritis, with a favorable balance of benefit and risk, then this class of compounds may become a prominent addition to the options for therapy of osteoporosis and other skeletal disorders.
    Therapeutic advances in musculoskeletal disease 04/2014; 6(2):48-57. DOI:10.1177/1759720X13510479
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to analyze sclerostin in plasma and synovial fluid of knee osteoarthritis (OA) patients and to investigate the association between sclerostin levels and the radiographic severity. A total of 190 subjects (95 knee OA patients and 95 healthy controls) were recruited in the present study. Sclerostin levels in plasma and synovial fluid were assessed using an enzyme-linked immunosorbent assay. OA grading was performed using the Kellgren-Lawrence classification. Plasma sclerostin levels were significantly lower in OA patients than in healthy controls (P=0.004). Additionally, sclerostin levels in plasma were significantly higher with respect to paired synovial fluid (P<0.001). Moreover, sclerostin levels in plasma and synovial fluid demonstrated significant inverse correlation with the radiographic severity of knee OA (r=-0.464, P<0.001 and r=-0.592, P<0.001, respectively). Subsequent analysis revealed that there was a positive correlation between plasma and synovial sclerostin levels (r=0.657, P<0.001). Sclerostin was significantly lower in OA plasma samples when compared with healthy controls. Plasma and synovial fluid sclerostin levels were inversely associated with the radiographic severity of knee OA. Therefore, sclerostin may be utilized as a biochemical marker for reflecting disease severity in primary knee OA.
    Clinical biochemistry 03/2014; 47(7-8). DOI:10.1016/j.clinbiochem.2014.03.011 · 2.23 Impact Factor